SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-038509
Filing Date
2023-05-11
Accepted
2023-05-11 16:01:14
Documents
13
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea178381-8k_tffpharma.htm   iXBRL 8-K 37124
2 PRESS RELEASE DATED MAY 11, 2023 REGARDING THE REGISTRANT'S FINANCIAL RESULTS FO ea178381ex99-1_tffpharma.htm EX-99.1 70181
  Complete submission text file 0001213900-23-038509.txt   294079

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tffp-20230511.xsd EX-101.SCH 2962
4 XBRL LABEL FILE tffp-20230511_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tffp-20230511_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea178381-8k_tffpharma_htm.xml XML 3702
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 23910759
SIC: 2834 Pharmaceutical Preparations